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Introduction
Part 1 of this series discussed NSAIDs, paracetamol, and 
topical analgesics as the treatment classes of choice for mild-
to-moderate pain. Moderate-to-severe pain necessitates 
consideration of multimodal analgesia, and the use of opioids 
in this setting may be necessary. Part 2 will discuss the opioid 
class of drugs, as well as drugs that modulate neurotransmitters 
in addition to opioid-activity (tramadol and tapentadol).
Pain is a complex and distinctive experience. It includes several 
pathways, involving nociceptive signal generation (transduction) 
and propagation (transmission), as well as perception and 
modulation of the nociceptive stimuli.1 Pain can been classified 
according to several approaches,2–4 including: acute, chronic, or 
breakthrough; cancer or non-cancer; nociceptive, neuropathic, 
or mixed; or according to intensity (mild, moderate, severe). Of 
these, acute or chronic pain is probably the most commonly 
assigned classification. Acute and chronic pain were previously 
seen as separate entities, and delineated according to duration.5,6 
However, better understanding of the complexity of pain is 
expanding and questioning this simplified distinction.7 Acute 
pain is seen as an accepted part of life, and serves as a protective 
function to prevent further injury and promote tissue healing.8 
Chronic pain was previously defined as lasting more than 6 
months,6 but has been amended to “pain that lasts beyond the 
healing of injured tissue and the related inflammatory processes”.8 
Chronic pain has a significant impact on quality of life9 and 
places a significant burden on both patients and the healthcare 
sector.10 While acute pain was previously seen as distinct from 
chronic pain, it is now recognised that the transition of acute 
to chronic pain (termed pain chronification) may actually be a 
continuum,11 and that the underlying mechanisms of pain may 
be more important than duration in its development.5
The mechanisms of pain chronification are not fully understood, 
and risk factors for its development remain unclear. Proposed 
mechanisms involve sensitization of nociceptive neurons, and 
these may be present peripherally and/or centrally.5 Peripheral 
sensitization appears to be induced by persistent stimulation 
of primary afferent nociceptive neurons leading to neuroplastic 
changes of the nerves.12 These changes confer increased 
responsiveness6 and protracted hypersensitivity of peripheral 
nociceptive neurons (termed “hyperalgesic priming”),13 and 
constitutes the development of primary hyperalgesia, which 
leads to steady stimulation of the secondary afferent neurons in 
the dorsal horn, and may result in secondary hyperalgesia and 
the development of central sensitization.14 This, however, does 
not fully explain why only some patients with peripheral and/
or central sensitization develop chronic pain. Consequently, 
pain chronification seems to involve other processes as well, 
such as changes in pain modulation, neuroplasticity, and pain 
perception (neuromatrix).5
Chronic pain is therefore multifactorial in origin, and involves 
multiple sites in the nervous system. This is the rationale for 
multimodal analgesia,15 and can be applied to both acute and 
chronic pain. Pain management was previously approached with 
substantial reference to the World Health Organization (WHO) 
analgesic ladder.16 The recommended escalation of analgesia by 
adding increasingly potent opioid drug classes to non-opioids 
was developed for cancer pain, but has subsequently also been 
applied to non-cancer pain. While this stepwise approach may 
provide a good foundation for universal access to analgesia, 
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Abstract
Pain can be caused by several mechanisms, and the development of chronic pain (also known as pain chronification) is a complex 
and often unpredictable process. Opioids, tramadol, and tapentadol provide pharmacological solutions to chronic pain of cancer 
or non-cancer origins, particularly if central sensitization is present. It may also be indicated for short-term use in acute pain. 
Despite large studies and meta-analyses of opioids for a variety of pain conditions, the evidence for its clinical effectiveness is 
still unclear. This is, however, mostly due to significant heterogeneity and bias between studies assessed. The dual analgesic 
mechanisms of tramadol and tapentadol appear to be effective options for pain relief, with an overall lower incidence of opioid-
related adverse effects. Tapentadol has an analgesic effect comparable to the strong opioids, which appears to be mediated by its 
greater mu opioid receptor activity and more selective noradrenaline reuptake inhibition. Tramadol produces less analgesia than 
tapentadol, but it is also associated with reduced opioid-related adverse effects and dependence. The opioids and tramadol may 
be significantly affected by polymorphisms of CYP2D6, while this effect is lessened with tapentadol.
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it leaves some gaps, specifically that adequate analgesia is 
not achieved in many patients,17 and that newer analgesic 
techniques (such as neuraxial procedures) are not incorporated. 
This in turn may contribute to the development of chronic pain. 
A new, bidirectional ladder has therefore been proposed to 
address acute pain adequately, and to optimise the management 
of chronic pain.18 It makes provision for both cancer and non-
cancer pain, and provides a “start high-step down” approach for 




The opioids comprise a diverse range of naturally occurring, 
semi-synthetic or synthetic compounds. These drugs have 
varying degrees of potency and can act as agonists (e.g. 
morphine, oxycodone, hydromorphone, codeine), partial 
agonists (e.g. buprenorphine), or antagonists (e.g. naloxone) 
at the opioid receptors.19 The opioid receptors are classified as 
mu, kappa, and delta, and revision by the International Union 
of Pharmacology (IUPHAR) in 2000 expanded the names to 
include the interchangeable terms MOP (mu opioid peptide), 
KOP (kappa opioid peptide) and DOP (delta opioid peptide) 
receptors.20 A fourth receptor NOP (nociceptin opioid peptide) 
was later discovered, but its significance is currently not well 
defined.20
The analgesic effects of the opioid agonists are largely mediated 
by activation of the mu receptors. This activation is also 
responsible for most of the adverse effects related to opioid 
use, and includes sedation, respiratory depression, nausea, and 
vomiting.19 Opioid-mediated analgesia originates primarily in 
the central nervous system,1,15,19 where it stimulates descending 
inhibition in the midbrain with the downstream effect of 
attenuating ascending nociceptive signals in the dorsal horn 
of the spinal cord (Figure 2). Opioids also stimulate dorsal horn 
nerve fibres and other peripheral nociceptors directly, further 
attenuating ascending signals.21 The central analgesic effects 
of opioids also appear to be mediated by modulation of pain 
perception within the neuromatrix.
Clinical responses to opioids vary and may be related to the 
type of pain, medical conditions, concomitant drugs, and 
Figure 1: Modified analgesic ladder18
NSAIDs – Nonsteroidal anti-inflammatory drugs. PCA – Patient-controlled analgesia
Figure 2: Opioid, tramadol, and tapentadol targets (adapted from Marsh22)
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patient metabolizer status.23 Metabolizer status may account for 
unexpected responses to opioids, but are difficult to predict as 
most opioids have complex metabolic pathways with varying 
degrees of active and inactive metabolites.23 A classic example 
is codeine, which exerts the primary analgesic effect via its 
metabolism to morphine that has a 200 times greater affinity for 
the mu receptor than codeine itself.24 This biotransformation is 
mediated by cytochrome P450 (CYP) 2D6 enzymes, and the gene 
encoding these enzymes is highly polymorphic.25 Consequently, 
based on CYP2D6 enzyme activity, patients can be classified 
as either poor, extensive, or ultrarapid metabolizers. Poor 
metabolizers are not able to readily convert codeine to morphine, 
and may therefore not achieve adequate analgesia.24 Conversely, 
ultrarapid metabolizers may generate toxic concentrations of 
morphine and, following several case reports of this effect, the 
American Food and Drug Administration (FDA) released a safety 
announcement restricting its use in children and breastfeeding 
mothers.26 The prevalence of CYP2D6 poor and ultrarapid 
metabolizers in the general population is estimated to be 5–10% 
and 1–2%, respectively.25
Pharmacogenetic factors may explain some of the interindividual 
variation of opioid effects, but even after correcting for these and 
various other factors, individual responses still vary. Molecular 
studies have identified different mu receptor subtypes, and 
have suggested that this variability may be due to differential 
functional activation by opioids, as well as the receptor subtype 
localizations in the body.27
Place in therapy: Cancer pain
The management of cancer pain is universally recommended 
to include a multimodal approach,28 encompassing not only 
multiple pharmacological modalities (if needed), but also 
including patient education and social structure support. Various 
international bodies have released guidelines on the principles 
of cancer pain management, and principles relating to opioids 
are broadly summarized in Table 1.29-32
Table 1: Summarized recommendations for opioid use in cancer pain 
management
Patient-specific goals for pain management need to be considered, 
and the undertreatment of pain prevented.
Persisting or new pain requires comprehensive assessment for 
possible cause, identification of a pain syndrome, and patient goals.
Oral analgesics are preferred, but pain that requires urgent relief may 
be managed with parenteral opioids. The use of modified-release 
opioids for acute pain is discouraged.
In mild to moderate pain not controlled by NSAIDs, a weak oral 
opioid (codeine or tramadol) may be added according to the WHO 
analgesic ladder.
In moderate to severe pain strong opioids may be added, but there is 
no preference between morphine, oxycodone, and hydromorphone.
Switching between different opioids is frequently done in practice for 
inadequate pain relief or severe adverse effects, but is not supported 
by strong evidence.
For maintenance analgesia, regular doses of opioids are 
recommended, with rescue doses as needed. The management of 
adverse effects (e.g. constipation), and support structures for patients 
and families are also strongly advocated.
NSAIDs: Nonsteroidal anti-inflammatory drugs. WHO: World Health Organization
The effectiveness and safety of opioids for cancer pain was 
assessed in a 2017 systematic review of nine previously 
conducted systematic reviews, and included around 
120 studies.33 The authors state that the effectiveness of opioids 
for cancer pain was difficult to interpret due to significant 
heterogeneity of the studies. However, given extensive clinical 
experience and the available data, they concluded that for 
pooled effects of the different opioids, around 95% of patients 
with moderate or severe pain who are given opioids – and can 
tolerate these – should have their pain reduced to mild or no 
pain within 2 weeks. The review also found that most patients will 
experience opioid-related adverse effects, and that 10–20% of 
these patients will find the adverse effects intolerable, leading to 
a change in treatment. Of note is that the effectiveness and safety 
of opioids in these studies were evaluated over a short period of 
time (weeks). A recent article addressed this lack of evidence of 
long-term opioid use in cancer pain and highlighted the need for 
more robust data.34 The current opioid epidemic that started in 
the late 1990s35 has highlighted the risk of opioid dependence, 
and concern for dependence in the cancer population has been 
expressed.36 However, the 2015 American National Survey on 
Drug Use and Health37 surveyed the use of prescription opioids 
and found that a higher prevalence of prescription opioid use 
without misuse was present in those with cancer compared to 
those without cancer (93.9% vs 87.0%). Cancer patients also had 
a lower prevalence of opioid misuse without use disorders (5.3% 
vs 10.8%) and opioid use disorders (0.8% vs 2.2%) compared to 
those without cancer.
Place in therapy: Non-cancer pain
The role of opioids for cancer pain is clearly defined, but the risks 
and benefits of opioids in acute and chronic non-cancer pain 
is less well established. Opioids for acute pain are frequently 
prescribed in the postoperative period, emergency department, 
and primary care setting.38 While opioids can be very effective 
in these environments, the current opioid epidemic has 
illuminated how injudicious use of opioids in the acute setting 
may lead to chronic use and dependence. It is therefore prudent 
to use opioids selectively for acute pain from the choice of 
available analgesics. General principles relating to acute opioid 
prescriptions are to use opioids only for moderate to severe pain 
at the lowest effective dose for the shortest possible duration, 
the use of immediate-release formulations of opioids, and 
to consider multimodal, opioid-sparing management where 
applicable.32,39
A 2018 systematic review and meta-analysis40 of 96 randomised 
controlled trials assessed opioids for chronic non-cancer pain, 
and included studies of neuropathic pain, nociceptive pain, 
mixed pain, and central sensitization (defined as pain that is 
present in the absence of tissue damage). The review found an 
overall small improvement in pain and physical functioning, 
but this did not reach clinical significance. An increased risk of 
vomiting, compared with placebo, was also found. Another 
systematic review and meta-analysis assessed the evidence of 
opioids for neuropathic pain.41 The findings showed significant 
efficacy over placebo, although small sample size and short study 
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duration likely introduced significant bias. The comparison of 
opioids to placebo for neuropathic pain also does not reflect best 
current practice, as other drugs (such as the anti-epileptics and 
antidepressants) have shown superior efficacy for neuropathic 
pain. The use of these and other drugs in neuropathic pain, as 
well as the proposed pathophysiological mechanisms, will be 
discussed in Part 3 of this series. Further systematic reviews 
assessing opioids for osteoarthritis of the knee or hip,42 or for 
chronic low-back pain,43 found corresponding results: opioids 
may have a small benefit for pain relief, but low quality studies 




Tramadol is a centrally acting atypical opioid, as it has both opioid 
and neurotransmitter reuptake inhibition activity contributing 
additively to its analgesic effect.44 Tramadol is peculiar in that 
the analgesia produced by mu opioid receptor stimulation is 
primarily due to an active metabolite (M1) generated by the 
CYP2D6 enzyme,44-46 whereas the parent drug – while having 
some opioid receptor activity – is largely responsible for 
neurotransmitter reuptake inhibition.47 Tramadol is metabolized 
to over 20 metabolites, but only M1 as an active metabolite is 
regarded as significant.48
Tramadol is a racemic mixture of (+) tramadol and (-) tramadol, 
with the (+) enantiomer forming the active M1 metabolite.44 
The (+) enantiomer is also thought to be primarily responsible 
for serotonin reuptake inhibition,49 while the (-) enantiomer 
appears to largely mediate noradrenaline reuptake inhibition.50 
This inhibition of serotonin and noradrenaline reuptake is 
thought to enhance descending inhibition pathways in the 
spinal cord,44 while opioid receptor agonism produces analgesia 
by mechanisms described earlier (Figure 2). The dual analgesic 
mechanism of tramadol is further suggested by evidence that 
naloxone, an opioid antagonist, only partially reverses tramadol’s 
analgesic effect.51
Place in therapy
The potency of parenteral tramadol compared to morphine is 
in the range of 10%. Oral tramadol has a higher bioavailability 
than oral morphine, and its potency is estimated to be about 
20% of morphine.52 Tramadol appears to be equipotent to 
codeine at therapeutic doses.44,52 Tramadol does, however, have 
significant inter-individual variability of efficacy and adverse 
effects.53 This may be related to CYP2D6 polymorphisms, with 
poor metabolizers at an increased risk for inadequate analgesic 
response,54 and extensive or ultrarapid metabolizers possibly 
experiencing more adverse effects.53 Drugs that are inhibitors or 
inducers of CYP2D6 may also contribute to the wide variability.55 
Nausea and dizziness are frequent adverse effects of tramadol,52 
but its effect on respiratory depression, as well as dependence 
and abuse potentials, are low compared to morphine.56 Of note 
is that tramadol appears to lower the seizure threshold, and the 
risk of seizure is increased with concomitant use of other seizure 
threshold-lowering drugs.57 The increase in serotonin induced by 
tramadol may theoretically cause serotonin syndrome, but this is 
rarely seen with tramadol as monotherapy, and occurs in practice 
when other enhancers of serotonin are co-administered.58
Tramadol is frequently used to treat acute and chronic pain. 
For cancer pain management it is part of step 2 of the WHO 
analgesic ladder.16 The efficacy of tramadol for moderate to 
severe acute pain has been well described,59,60 and the addition 
of non-opioid analgesics (such as paracetamol or an NSAID) 
appears to potentiate its effects.61,62 Several systematic reviews 
have assessed the efficacy of tramadol in chronic pain conditions 
including osteoarthritis,63 neuropathic pain,64 and cancer pain.65 
A small beneficial effect of tramadol was noted in the analyses 
of these conditions, but its interpretation and application in 
clinical practice is limited by low quality evidence, and significant 
heterogeneity and small sample sizes of the studies.
Tapentadol
Mechanism of action
Tapentadol is a new generation atypical opioid that was 
recently registered in South Africa as a non-racemic, schedule 
6 medication. Its design was based on the additive dual mu 
opioid receptor and neurotransmitter reuptake inhibition 
mechanism of tramadol, but with greater focus on noradrenaline 
than serotonin reuptake inhibition.66 The rationale for this is 
based on several studies in animal and human models indicating 
that increasing noradrenaline concentrations in the spinal cord 
lead to greater analgesic effects compared to serotonin.66-68 In 
animal models, noradrenaline reuptake inhibition appears to be 
particularly significant to the attenuation of neuropathic pain.69 
Tapentadol is an active drug and, contrary to tramadol, its dual 
activity is not dependant on metabolism to active metabolites 
for its analgesic effect.55 Polymorphisms of CYP2D6, as well as 
drugs that are inhibitors or inducers of CYP2D6, are therefore not 
expected to cause significant inter-individual variability.55
Place in therapy
Tapentadol is only available as an oral formulation, and its 
analgesic potency compared to morphine is estimated to be 
around 40%.70 This translates to a significant relative increase 
in the analgesic effect compared to tramadol, but clinically 
tapentadol is compared to oxycodone, hydromorphone, and 
morphine.71 There is a paucity of data of head-to-head studies 
comparing tapentadol to tramadol, and this appears to be due to 
tapentadol’s increased analgesic effect leading to comparisons 
to strong opioid drugs. The potentiated analgesia attained 
appears to be due to tapentadol’s increased mu opioid receptor 
activity, more potent inhibition of noradrenergic reuptake, and 
a synergistic – rather than additive – combined effect.72 Clinical 
and post-marketing studies have found that tapentadol has less 
opioid-related adverse effects compared to the strong opioids,71 
but the prevalence compared to tramadol still is significantly 
more.73 
Tapentadol has shown favourable efficacy to the strong 
opioids,71,74,75 but this mostly relates to chronic or recurrent pain 
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(cancer and non-cancer), and may be overstated when subjected 
to systematic reviews.76,77 Tapentadol also has selected advantages 
over the strong opioids, including lower risk of dependence and 
abuse potential, less opioid-related adverse effects, and low risk 
of pharmacokinetic drug interactions.66,71,74,75,78,79
Summary
Analgesia for moderate-to-severe pain may require the use of 
opioids, tramadol, or tapentadol. Comprehensive management 
of chronic pain may need a multimodal approach, as the 
underlying processes that drive pain chronification appear to 
be more complex and poorly localized. The evidence for the 
recommendation of opioids in cancer and non-cancer pain is 
limited by heterogeneity of studies and frequent adverse effects, 
but clinical experience indicates that opioids are effective 
for moderate-to-severe pain. Opioid dependence is a global 
concern, but current evidence indicates that opioid use for 
cancer pain is effective without a significant risk of dependence. 
Tramadol and tapentadol are newer, atypical opioids that are 
mu receptor agonists as well as neurotransmitter reuptake 
inhibitors. Tramadol exerts both serotonin and noradrenaline 
reuptake inhibition in addition to opioid activity, but adverse 
effects of nausea and dizziness are frequent. Tapentadol has 
increased analgesic effects compared to tramadol. This appears 
to be mediated by tapentadol’s more potent opioid activity and 
more selective noradrenergic reuptake inhibition, subsequently 
making it comparable to the strong opioids. Tapentadol has less 
opioid-related adverse effects and dependence compared to 
the strong opioids, but these effects are still significantly more 
compared to tramadol. For drugs that are metabolized to an 
active form (such as tramadol or codeine), metabolizer status 
may significantly impact the effectiveness and safety of these 
drugs.
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